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ABSTRACT
Polygenic risk scores (PRSs) are a method to summarize the additive trait variance
captured by a set of SNPs, and can increase the power of set-based analyses by lever-
aging public genome-wide association study (GWAS) datasets. PRS aims to assess
the genetic liability to some phenotype on the basis of polygenic risk for the same or
diﬀerent phenotype estimated from independent data. We propose the application of
PRSs as a set-based method with an additional component of adjustment for linkage
disequilibrium (LD), with potential extension of the PRS approach to analyze biolog-
ically meaningful SNP sets. We call this method POLARIS: POlygenic Ld-Adjusted
RIsk Score. POLARIS identiﬁes the LD structure of SNPs using spectral decompo-
sition of the SNP correlation matrix and replaces the individuals' SNP allele counts
with LD-adjusted dosages. Using a raw genotype dataset together with SNP eﬀect
sizes from a second independent dataset, POLARIS can be used for set-based anal-
ysis. MAGMA is an alternative set-based approach employing principal component
analysis to account for LD between markers in a raw genotype dataset. We used simu-
lations, both with simple constructed and real LD-structure, to compare the power of
these methods. POLARIS shows more power than MAGMA applied to the raw geno-
type dataset only, but less or comparable power to combined analysis of both datasets.
POLARIS has the advantages that it produces a risk score per person per set using all
available SNPs, and aims to increase power by leveraging the eﬀect sizes from the
discovery set in a self-contained test of association in the test dataset.
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1 INTRODUCTION
Polygenic risk scores (PRSs) are now widely used for a vari-
ety of purposes in assessing the genetic liability to disorders or
more general phenotypes. These include sample stratiﬁcation,
risk prediction, and the detection of relationships between
diﬀerent subphenotypes (see, e.g., Allardyce et al., 2017;
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Escott-Price et al., 2015, and Foley et al., 2017, respectively).
The PRS method can also be adapted to partition the poly-
genic risk based on meaningful SNP sets, such as genes or
biological pathways, and to determine whether a set of SNPs,
weighted with their individual genetic risk eﬀects, is associ-
ated at the whole-genome or set-speciﬁc levels. In contrast to
set analysis that aims to analyze the joint association of SNPs
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with a single phenotype, PRS aims to assess the genetic lia-
bility to some phenotype on the basis of the polygenic risk for
the same or a diﬀerent phenotype estimated from independent
data.
Set-based analysis oﬀers an attractive alternative to sin-
gle SNP analyses, because the combined eﬀect of SNPs
within the set may be captured. Single SNP analyses are often
underpowered due to the small eﬀect sizes of individual SNPs,
set-based analysis considers the combined eﬀect of all SNPs
within the set, which may have a larger combined eﬀect size
and hence higher power to detect association than any indi-
vidual SNP. In addition, gene-based analysis, a gene-centered
equivalent of set-based analysis, identiﬁes genes associated
with disease rather than a single SNP as a proxy for the gene.
In gene-based analyses, genes are found to be fairly consis-
tently associated with disease across diﬀerent populations.
In contrast, diﬀerent SNPs in a set in linkage disequilibrium
(LD) may be found to be associated with a disease in diﬀerent
samples. Gene-based analyses also directly provide informa-
tion for functional analysis (Li, Gui, Kwan, & Sham, 2011).
Set-based analysis can also be employed as a pathway anal-
ysis, and applied to sets of SNPs deﬁned by epigenomics for
diﬀerent tissue/cell types.
There are a number ofmethods to assess the set-based eﬀect
by combining the eﬀects of all SNPs within the set, including
Fisher's method (Elston, 1991) for combining P values assum-
ing independence between SNPs, Simes's method (Simes,
1986) for ﬁnding the smallest adjusted P-value, GATES
extended Simes (Li et al., 2011) that incorporates functional
information, rank/threshold truncated products of p meth-
ods (Dudbridge & Koeleman, 2003; Moskvina et al., 2009;
Zaykin, Zhivotovsky, Westfall, & Weir, 2002), set-based anal-
ysis as implemented in PLINK (Chang et al., 2015; Purcell
et al., 2007), Brown's method (Brown, 1975; Moskvina et al.,
2011) that adjusts for the LD structure between SNPs, a logis-
tic kernel-machine based test that accounts for nonlinear SNP
eﬀects (Wu et al., 2010), MAGMA (de Leeuw, Mooij, Heskes,
& Posthuma, 2015) that uses a regression-based approach and
Pascal (Lamparter, Marbach, Rueedi, Kutalik, & Bergmann,
2016) that utilizes the sum and maximum of chi-squared
statistics to generate a set score. Each of these methods have
advantages and limitations, however, the above methods do
not incorporate the eﬀect sizes from external data with indi-
vidual genotype data. Set-based methods using individual
SNP P values are also able to improve power by incorporat-
ing external data available from previous studies using meta-
analysis. In the present paper, we focus on methods which use
individual genotype data as this is a necessary requirement of
PRS.
MAGMAv1.06 (de Leeuw et al., 2015) is a recent approach
that has emerged as a widely used and computationally
eﬃcient set-based method. This regression-based approach
accounts for LD between SNPs when individual genotype
data are available. Thematrix of SNPswithin the set is decom-
posed into principal components (PCs), and PCs with small
eigenvalues are removed. The remaining PCs are then used
as uncorrelated predictors in regression against the pheno-
type of interest and an F-test is used to determine the strength
of the association between the set and the phenotype, pro-
viding the MAGMA set-based P-value. The MAGMA pro-
gramme can be used on individual genotypes using the Princi-
pal Component Analysis (PCA) method and also on summary
statistics using Brown's method (Brown, 1975). It often hap-
pens that summary statistics are available from a large consor-
tium, while in-house studies with individual genotypes have
smaller sample sizes. In such situations, the options for using
MAGMA are either applying the PCA method to the in-house
genotype dataset, or to a meta-analysis of the summary statis-
tics for both datasets.
PRS analysis can be considered as set-based analysis when
a set includes all SNPs in the whole genome. PRSs provide a
method for combining information from individual SNPs into
a single measure of risk allele burden. In their most widely
used form, PRS's have been applied to genome-wide SNP
data where they can capture a useful fraction of genetic lia-
bility to polygenic traits. PRS's can also be used as genome-
wide predictors of aﬀected status (Escott-Price et al., 2015;
Purcell et al., 2009; Ripke et al., 2014). We reasoned that
the basic principles of polygenic score analysis can also be
applied to individual genes, or to gene-set analyses. The moti-
vation for doing so is somewhat diﬀerent than PRS analyses
of genome-wide data; rather than predict case–control sta-
tus or trait liability captured, our goal in applying the prin-
ciples of PRS to genes and gene sets is to detect association
to these potentially biologically informative features. As for
genome-wide analyses, genes or gene-set PRS could be used
to predict aﬀected status, or to estimate the gene- or pathway-
speciﬁc SNP liability captured by GWAS. However, for poly-
genic disorders where risk is dispersed across hundreds of
genes andmultiple gene sets, self-evidently, gene- or pathway-
speciﬁc SNP liability will be lower than the liability cap-
tured by genome-wide data, and accordingly, such tests will
aﬀord less case-control discriminatory power. Risk scores for
each individual per set can be used to stratify individuals for
follow-up studies and prioritize genes for further functional
studies.
In this paper, we suggest a novel approach to a set-based
framework that combines advantages of MAGMA's PCA
method and PRS. The proposed POlygenic LD-Adjusted RIsk
Score (POLARIS) method aims to improve upon the standard
PRS method by correcting the inﬂated Type I error observed
both in standard PRS in the presence of LD (Chatterjee et al.,
2013), and also in set-based analyses as the number of SNPs in
the set grows (de Leeuw, Neale, Heskes, & Posthuma, 2016).
We use spectral decomposition of the SNP correlation matrix
to adjust the individuals' allele counts for LD structure. In
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this paper, POLARIS is presented as a self-contained set-
based approach in that it compares the test statistic for the set
with the null hypothesis, rather than a competitive approach
that accounts for the baseline level of association across the
genome. However, it can be turned into a competitive method
either by including a general PRS in the analysis, or compar-
ing the set-based PRS to those generated from random sets of
genes (matched for number of SNP-sets/set size/numbers of
SNPs).
POLARIS informs the analysis with previously reported
eﬀect sizes of the SNPs' association with disease. An LD-
adjusted PRS is calculated per person per set, and the over-
all set eﬀect is computed using regression. Because the score
is used as a predictor in a regression analysis, it is possi-
ble to include further population covariates or any other pos-
sible confounders. POLARIS uses all available information,
because all PCs are incorporated into a score, thus avoid-
ing overﬁtting that may result from only including the top
PCs. As in standard PRS analysis, only one independent vari-
able (apart from extra covariates) is present in the regression
model, rather than the number of predictors being equal to
the number of markers, or the number of chosen PCs. Like
the standard PRS approach, an advantage of our method is
that it performs a self-contained test of association in the test
dataset, leveraging the discovery set to increase the power of
this test. A signiﬁcant test statistic implies signiﬁcant associ-
ation speciﬁcally in the test sample, unlike a signiﬁcant meta-
analysis result, where the association evidence could result
from other samples. This might be important if the test sam-
ple is of speciﬁc interest, for example, a diﬀerent ethnicity, or
a diﬀerent, but related, phenotype.
In the present paper, POLARIS is evaluated by comparing
the set-based results calculated using LD-adjusted PRS with
those found using MAGMA (de Leeuw et al., 2015) on sim-
ulated data, both with a simple constructed LD structure and
real data LD pattern.
The POLARIS set-based analysis tool is available to down-
load from github.com/BakerEA/POLARIS. The tool is writ-
ten in Python and will operate on any computing platform.
2 METHODS
2.1 POLARIS rationale and derivation
For 𝑀 SNPs in a set, the standard PRS combines single-SNP
genotypes 𝑔𝑖 (𝑖 = 1,… ,𝑀) into a single regression predictor
using single-SNP eﬀect sizes (log(OR𝑖) = 𝛽𝑖) taken from a
previous study as coeﬃcients,
𝑃𝑅𝑆 =
𝑀∑
𝑖=1
𝛽𝑖𝑔𝑖 = 𝛽𝑇 𝑔. (1)
This method implements a two-stage approach, where inde-
pendent discovery and test sets are available. The eﬀect sizes
𝛽 are determined from the discovery set and vector of the num-
ber of risk alleles 𝑔 is obtained from the test set. The underly-
ing assumption is that individual genotypes are available for
the test set, but only summary data (eﬀect sizes 𝛽) for the dis-
covery set are available.
The standard PRS method does not adjust for LD between
markers and thus requires LD pruning (Chatterjee et al.,
2013). If markers are in LD, the simple weighted sum
(Equation 1) may give them undue weight; indeed, if they are
in positive LD, they are likely to have a similar single-SNP
eﬀect size and act together, thus giving a larger contribution
to the PRS than a single or uncorrelated marker.
We correct for this imbalance due to LD by replacing the
vector 𝑔 of genotypes with a vector ?̃? of adjusted dosages.
Consider the spectral decomposition of the 𝑀 ×𝑀 marker–
marker correlation matrix 𝐶 ,
𝐶 =
𝑀∑
𝑘=1
𝜆𝑘 𝑥𝑘 𝑥
𝑇
𝑘
with eigenvalues 𝜆𝑘 satisfying
∑𝑀
𝑘=1 𝜆𝑘 = tr 𝐶 = 𝑀 and
orthonormal (column) eigenvectors 𝑥𝑘. The correlation
matrix is the covariance matrix of the joint distribution of
individual genotypes after standardization of each SNP. Its
eigenvectors indicate the directions of the principal axes of
this standardized distribution, and the corresponding eigen-
values give the variances of the distribution in the correspond-
ing directions. In the absence of LD, these variances will be
equal to 1, and the distribution will be isotropic. However, if
there is LD, then these variances will in general be diﬀerent,
and the standardized distribution will be more elongated in
some principal directions and ﬂattened in others.
This anisotropy can be removed by scaling the standard-
ized joint distribution in the direction of each principal axis
with the inverse square root of the eigenvalue in this direction.
However, adjusting the standardized distribution in this way
will not only remove LD, but also equalize the single marker
variances, thus discarding information such as theminor allele
frequencies. As our aim is to adjust for LD only, but not for
single-SNP variances, we therefore have chosen to apply the
same scaling transformation to the original, unstandardized
joint distribution instead.
More speciﬁcally, due to the orthonormality of the eigen-
vectors, the PRS can be expressed in a spectral decomposition
𝑃𝑅𝑆 = 𝛽𝑇 𝑔 =
𝑀∑
𝑘=1
𝛽𝑇 𝑥𝑘 𝑥
𝑇
𝑘
𝑔.
The component 𝑥𝑘 𝑥
𝑇
𝑘
𝑔, which is the part of 𝑔 along the 𝑘th
principal axis, has correlation matrix eigenvalue 𝜆𝑘 and there-
fore contributes a disproportionate amount of variance to PRS
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unless 𝜆𝑘 ≈ 1. For an uncorrelated marker, one spectral com-
ponent will be concentrated on this marker, and the corre-
sponding eigenvalue 𝜆𝑘 ≈ 1.
For our adjustment, we rescale the coordinate of 𝑔 in the
direction of the 𝑘th principal axis, 𝑥𝑇
𝑘
𝑔, with the inverse
square root of the correlation eigenvalue, giving an adjusted
coordinate
1√
𝜆𝑘
𝑥𝑇
𝑘
𝑔, and hence the rescaled spectral compo-
nent
1√
𝜆𝑘
𝑥𝑘 𝑥
𝑇
𝑘
𝑔.
Applying this adjustment to each principal axis will result
in an isotropic distribution in which the correlation has mostly
been removed, for the adjusted dosage vectors
?̃? =
𝑀∑
𝑘=1
1√
𝜆𝑘
(𝑥𝑇
𝑘
𝑔) = 𝐶−
1
2 𝑔.
Note this adjustment of multivariate data by correlation is
analogous to the calculation of the Mahalanobis distance
for mean zero data 𝑥, 𝑥𝑇𝑆−1𝑥 = ‖𝑆−12 𝑥‖2, where 𝑆 is the
covariance matrix (Mahalanobis, 1936, see also Hotelling,
1931), except that here we use the correlation matrix instead
of the covariance matrix in order to avoid adjusting for single-
marker variance.
Using the adjusted dosages ?̃? instead of the original geno-
type vectors 𝑔, we obtain an LD-adjusted PRS
𝑀∑
𝑖=1
𝛽𝑖𝑔𝑖 = 𝛽𝑇 ?̃? = 𝛽𝑇 𝐶
−12 𝑔
=
𝑀∑
𝑖=1
𝛽𝑖
(
𝑀∑
𝑘=1
1√
𝜆𝑘
𝑥𝑘(𝑖)
𝑀∑
𝑗=1
𝑥𝑘(𝑗) 𝑔𝑗
)
.
In the sum over the spectral components, indexed by 𝑘, the
terms with 𝜆𝑘 = 0, corresponding to principal directions with
no variance, are to be omitted, resulting eﬀectively in a pseu-
doinverse of the square root of 𝐶 . In cases of extreme LD,
where 𝜆𝑘 ≈ 0, this formula will apply a large correction fac-
tor to the corresponding component, thus possibly amplify-
ing small deviations due to, for example, genotyping error. In
order to avoid this instability, we introduce a ridge parame-
ter 𝜆0, for which we suggest the choice 𝜆0 =
√
1
𝑁
, where 𝑁
is the number of individuals in the test data, and modify the
adjustment to mitigate the eﬀect of small 𝜆𝑘. This gives rise
to the POLARIS risk score,
POLARIS = 𝛽𝑇
√
1 + 𝜆0
(
𝐶 + 𝜆0𝐼
)−12 𝑔 (2)
=
𝑀∑
𝑖=1
𝛽𝑖
⎛⎜⎜⎝
𝑀∑
𝑘=1
√
1 + 𝜆0
𝜆𝑘 + 𝜆0
𝑥𝑘(𝑖)
𝑀∑
𝑗=1
𝑥𝑘(𝑗)𝑔𝑗
⎞⎟⎟⎠ = 𝛽𝑇 ?̃?, (3)
where now ?̃? =
√
1 + 𝜆0(𝐶 + 𝜆0𝐼)
− 12 𝑔 =
∑𝑀
𝑘=1
√
1+𝜆0
𝜆𝑘+𝜆0
𝑥𝑘
𝑥𝑇
𝑘
𝑔, and 𝐼 is the𝑀 ×𝑀 unit matrix. Note that if all markers
are uncorrelated, then 𝜆𝑘 ≈ 1 for all 𝑘, which makes ?̃? ≈ 𝑔,
and consequently POLARIS ≈ 𝑃𝑅𝑆.
We remark further that we applied the adjustment ?̃? =
𝐶
−12 𝑔 (or the extension with a ridge parameter) directly to
the vector of genotypes. More precisely, an adjustment of the
variance only will be achieved by removing the sample mean
vector ?̂? before the adjustment, giving
?̃? = ?̂? + 𝐶−
1
2 (𝑔 − ?̂?) = 𝐶−
1
2 𝑔 +
(
𝐼 − 𝐶−
1
2
)
?̂?;
however, this only amounts to shifting the POLARIS score
by a constant 𝛽𝑇 (𝐼 − 𝐶−
1
2 )?̂?, which is irrelevant in the subse-
quent regression analysis.
2.2 POLARIS: Set-based analysis applied to
simulated data
To understand detailed diﬀerences and similarities between
MAGMA (de Leeuw et al., 2015) and POLARIS, we tested
both methods on simulated data, both with a simple extreme
LD pattern and a real-data LD pattern between SNPs. We
tested Type I and II errors by simulating null eﬀects and
introducing some association to the SNPs, respectively. We
ran a set of experiments to compare the proposed POLARIS
method to MAGMA.
To generate summary statistic data and genotype data, a
simulated dataset was randomly split into discovery and test
sets. The summary statistics for each SNP in the discovery set
were computed. The following diﬀerent scenarios were simu-
lated.
• Scenario A (“One LD Block”): 10 SNPs in an LD Block
with (i) 𝑟2 = 0.2 and (ii) 𝑟2 = 0.8 between consecutive
SNPs. The “causal” SNP is associated with disease with
OR=1.1 and the remaining nine SNPs have an OR closer to
the null value of 1. An additional 90 independent unasso-
ciated SNPs are also present in the set, see supplementary
Figure S1 for LD structure.
• Scenario B (“Real Data LD”): 115 SNPs from real genetic
and environmental risk in Alzheimer's disease (GERAD)
data (Harold et al., 2009), see the next section for a detailed
description of the data and supplementary Figure S2 for LD
structure. For an SNP in a block of strong LD, a number
of controls who were homozygous for the risk allele were
set to cases, and an equal number of cases homozygous for
the protective allele were set to controls, thus producing an
association with disease.
For these scenarios, the sample size of the discovery
dataset was varied in order to determine the inﬂuence of the
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discovery set sample size on the POLARIS method. For Sce-
nario A, simulations were run creating data with N = 20,000
and 60,000 individuals, these were split equally to result in
a test and discovery set each with N = 10,000 and 30,000
subjects, respectively. Additionally, the larger set with 60,000
individuals was split such that the test set had N = 10,000 and
the discovery set had N = 50,000 individuals. Scenario B has
13,164 subjects for the combined discovery and test sets; we
divided these data 50/50 and 25/75. In both the discovery and
test datasets, 30% of the sample size were cases.
A total of 1,000 simulations were performed for each sce-
nario. The power to detect the association between the set and
disease is calculated as the proportion of P values from the
1,000 simulations that were below a given P-value threshold;
the P-value thresholds used were P = 0.05, 0.01, and 0.001.
Ten thousand simulations were used for the real data simula-
tions, thus enabling a more stringent threshold of 0.0001 to
be considered. The power of the POLARIS method, applied
to the test dataset and informed by the discovery dataset, was
compared to the power of MAGMA both applied to the test
dataset only and to the total unsplit data samples.
2.3 POLARIS: Gene-based analysis applied
to real data
Both POLARIS and MAGMA were applied to genotyped AD
data to determine gene-wide P values. The GERAD (Harold
et al., 2009) genome-wide association study (GWAS) data
(3,332 cases, 9,832 controls) were used as the test dataset.
International Genomics of Alzheimer's Project (IGAP) (Lam-
bert et al., 2013) data (17,008 cases, 37,154 controls) exclud-
ing GERAD subjects (IGAP-noGERAD) were used as the
discovery data in order to inform POLARIS with association
eﬀect sizes.
International Genomics of Alzheimer's Project (IGAP)
is a large study that used genotyped and imputed data on
7,055,881 single nucleotide polymorphisms (SNPs) to meta-
analyze four previously published GWAS datasets consisting
of 17,008 AD cases and 37,154 controls (The Genetic and
Environmental Risk in AD consortium-GERAD, The Euro-
pean Alzheimer's disease Initiative-EADI, the Alzheimer Dis-
ease Genetics Consortium-ADGC, and The Cohorts for Heart
and Aging Research in Genomic Epidemiology consortium-
CHARGE).
For this study, we used only directly genotyped SNPs from
theGERADdata (cf. Escott-Price et al., 2014, where however,
imputed genotype data were used for IGAP summary statis-
tics analysis). The GERAD and IGAP-noGERAD datasets
have 419,048 SNPs in common. It was necessary to ensure
that SNP alleles were coded in the same direction across both
the discovery (IGAP-noGERAD) and test (GERAD) datasets.
If alleles in IGAP-noGERAD were coded in the opposite
direction to those in GERAD, the summary eﬀect size for
the SNP was inverted. SNPs with alleles AT, TA, CG, or
GC were excluded because the direction of the eﬀect could
not always be determined when combining two studies. Of
the SNPs in IGAP-noGERAD, 103,356 matched those in
GERAD, the remaining had eﬀect sizes inverted and no SNPs
were excluded due to ambiguity. An MAF ﬁlter of 0.01 was
applied to the data.
The missing genotypes in real data were imputed as in
PLINK (Chang et al., 2015; Purcell et al., 2007), where miss-
ing genotypes are substituted by 2 ×𝑀𝐴𝐹 for each SNP. In
the GERAD data, 0.0514% of genotypes required imputation.
SNPs were assigned to genes using GENCODE (v19) gene
models (Harrow et al., 2012). Only genes with known gene
status and those marked as protein coding were used. No win-
dow was used around the gene, only SNPs within the start
and end position of the gene were included. SNPs that belong
to multiple genes were assigned to all those genes. A total of
202,504 SNPs were assigned to 14,620 distinct genes with a
maximum of 1,342 SNPs in a gene.
The results of gene-based analyses for Alzheimer's dis-
ease (AD) data using POLARIS were compared to those from
the MAGMA-PCA approach in GERAD genotype data and
also the MAGMA-SUMMARY approach in IGAP data (not
MAGMA-PCA, as the individual genotypes for the whole
IGAP data were not available to us). For the latter, we only
consider SNPs present in both IGAP and GERAD. Prior to
the gene-set analysis, SNP summary statistics for the whole
IGAP data were adjusted for the genomic control parameter,
𝜆=1.087, as reported in Escott-Price et al. (2014).
3 RESULTS
3.1 Set-based analysis: Applied to simulated
data
3.1.1 Type I error
We investigated the Type I error rates in simulations where
none of the SNPs have an association to disease (i.e., OR =
1) in either the discovery or test sets, for Scenarios A (one
LD block) and B (real data LD), termed A(null) and B(null),
respectively. Type I error is deemed acceptable if the nominal
value is included in the 95% CI for estimated Type I error rate.
The expected Type I error is displayed on the Type I error plots
(gray dashed line).
Figure 1 shows Scenario A(null). The LD structure for
Scenario A can be seen in supplementary Figure S1. Type I
error for POLARIS is shown by the blue bars (POLARIS),
the red bars (MAGMA D&T Geno) display the Type I error
for the MAGMA method in the combined discovery and test
individual genotype data and green bars (MAGMA T Geno)
show the Type I error for MAGMA in test set genotype data
only. In supplementary Figure S3, we additionally show the
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F IGURE 1 Type I error comparison of set-based methods at diﬀerent P-value thresholds; scenario A(null)—simulation of 10 SNPs in LD and
90 independent SNPs
Notes: POLARIS with no associated SNPs in both test and discovery sets (blue), MAGMA in the test set only (green), and MAGMA in combined test
and discovery sets (red). Expected Type I error is shown by the gray dashed line.
Type I error rate for summary statistics based analysis using
MAGMA (MAGMA D&T Summ).
The Type I error rate is reasonable in the majority of cases;
the nominal value is included in the 95% CI. MAGMA in the
combined data has slightly inﬂated Type I error at a P-value
threshold of 0.001 when the test and discovery set have N =
10000 and 𝑟2 = 0.2.
The Type I error for scenario B(null), with the case-control
status randomly permuted in order to remove the eﬀect size of
any SNPs, is shown in Figure 2 and supplementary Figure S4.
The LD structure for this scenario can be observed in supple-
mentary Figure S2. The Type I error rate is within 95% CIs of
expected values for most cases, but is somewhat inﬂated for
the summary statistic based analysis using MAGMA.
3.1.2 Power
The power of the POLARIS method (blue bars, POLARIS),
MAGMA in the test set only (green bars, MAGMA T Geno)
and MAGMA in the combined discovery and test sets (red
bars, MAGMA D&T Geno) are displayed for each simulated
scenario. The power graphs for Scenario A are shown in
Figure 3. The 10 SNPs that are in LD are associated with dis-
ease with OR = 1.1.
POLARIS has equivalent power compared with MAGMA
in the combined discovery and test sets in all cases. In the
most likely realistic situation, the discovery set is larger than
the test set, but only summary statistics are available for the
discovery set. MAGMA on the combined dataset has higher
power where the test N = 10,000 and discovery N = 50,000,
but here MAGMA is applied to the individual genotypes of
the discovery and test sets combined (N = 60,000), so the
sample used to estimate LD and perform the statistical test
is very large, whereas POLARIS uses the discovery set N =
50,000 for eﬀect size estimation and only N = 10,000 for LD
estimation, and importantly, for statistical testing. In all cases,
POLARIS has higher power than MAGMA in the test set only,
as is expected, because POLARIS increases power by incor-
porating information from the discovery set. The power for
POLARIS increases when the size of the test set increases, as
this improves the estimate of LD between markers.
Figure 4 shows the power graph for Scenario B. The power
of the POLARIS method lies generally between the power
of MAGMA applied to the test set only and MAGMA in the
combined test and discovery sets. One can see that by using
the information from the discovery set, POLARIS increases
the power compared to using the test set only, but, as is to be
expected, not as much as using the individual genotypes from
the discovery set as well as the test set.
These power results were also compared with the power
of the summary statistics based approach implemented in
MAGMA, see supplementary Figures S5 and S6. Note that the
power of the summary statistics based approach (MAGMA
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F IGURE 2 Type I error comparison of set-based methods; scenario B(null)—simulation of 115 SNPs from real data, with permuted phenotypes
to remove eﬀect sizes
Notes: POLARIS with no associated SNPs in either test or discovery sets (blue), MAGMA in test set only (green), and MAGMA in combined test and
discovery sets (red) are compared. Expected Type I error is shown by the gray dashed line.
F IGURE 3 Power comparison of set-based methods at diﬀerent P-value thresholds; scenario A—simulation of 10 SNPs in LD with OR=1.1
and 90 independent, unassociated SNPs
Notes: POLARIS (blue), MAGMA in the test set only (green), and MAGMA in combined test and discovery sets (red) are compared.
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F IGURE 4 Power comparison of set-based methods; scenario B—simulation of 115 SNPs, with a proportion of phenotypes permuted to main-
tain eﬀect sizes
Notes: POLARIS (blue), MAGMA in the test set only (green) and MAGMA in combined test and discovery sets (red) are compared.
TABLE 1 Comparison of the number and proportion of independent genes below a P-value threshold for POLARIS, MAGMA-PCA in GERAD
data and MAGMA-SUMMARY in IGAP data
POLARIS MAGMA-PCA in GERAD MAGMA-SUMMARY in IGAP
P-value threshold
Number
of genes
Proportion of
genes
Number
of genes
Proportion of
genes
number of
genes
proportion of
genes
1* 563 581 560
0.05 302 0.5364 283 0.4871 255 0.4554
0.01 116 0.2060 98 0.1687 114 0.2036
0.001 19 0.0337 12 0.0207 31 0.0554
0.0001 7 0.0124 4 0.0069 12 0.0214
0.00001 3 0.0053 2 0.0034 9 0.0161
0.000001 2 0.0036 1 0.0017 5 0.0089
*Note that the total number of genes (P-value threshold equal to 1) diﬀers, this is due to some gene exclusions made by MAGMA software.
D&T Summ) exceeds the power of MAGMA PCA (MAGMA
D&T Geno) on the same combined dataset.
3.2 Gene-based analysis: Application to real
data
Table 1 demonstrates the number and proportion of
genes below a particular P-value threshold for POLARIS,
MAGMA-PCA in GERAD genotype data and MAGMA-
SUMMARY in IGAP summary statistic data. Statistically
independent associations in some instances implicate over-
lapping regions. To deﬁne genes as physically independent,
we have annealed associated genes that were not separated
by at least 250 kb in each analysis separately. In the APOE
region, signiﬁcant genes on chromosome 19 between 44.4
and 46.5 Mb were counted as one. We also present the results
for all genes in supplementary Table S1.
The number of independent signiﬁcant genes for all P-
value thresholds is higher or equal for POLARIS com-
pared to the MAGMA-PCA approach in GERAD data.
This is expected as POLARIS uses both GERAD and
IGAP-noGERAD data, while MAGMA-PCA uses GERAD
genotypes only. The results for the summary statistic approach
show higher numbers of signiﬁcant genes for higher sig-
niﬁcance thresholds. The ﬁve gene-wide signiﬁcant genes
found by the summary statistics approach are: TOMM40,
CLU, BIN1, MS4A4E, and CR1, which have all been pre-
viously reported as being associated with AD from single
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SNP analyses (Harold et al., 2009 and Lambert et al., 2013).
For these ﬁve genes, POLARIS also ﬁnds an association, but
does not always reach gene-wide signiﬁcance (𝑃 = 6.33 ×
10−24, 𝑃 = 7.17 × 10−6, 0.00112, 0.00108, and 0.00065,
respectively).
The issue of bias in the estimation of set-based P values
caused by gene size is insuﬃciently tackled by most available
methods (de Leeuw et al., 2016; Ruderfer, 2013). Larger genes
harbor a larger number of SNPs, and if each SNP has a small
inﬂation in P-value due to, for example, unaccounted stratiﬁ-
cation, then these large genes will show greater accumulated
inﬂation. To assess whether this is an issue in POLARIS, the
phenotypes in GERAD data were permuted to create 1,000
simulations, and for each gene, the empirical P-value (the pro-
portion ofP values less than 0.05) was computed. The correla-
tion between the number of SNPs per gene and the empirical
P value of each gene in AD data was then determined. We
found no evidence (r = 0.0009, P = 0.9096) of a correlation
between the number of SNPs in a gene and the gene P-value
for the POLARIS method. Therefore, associations with dis-
ease observed in larger genes is not simply due to a greater
number of SNPs in the gene. Similarly, we observed no evi-
dence (r= –0.00321,P= 0.6977) of an inﬂation inP-value for
increasing gene size using MAGMA-PCA on GERAD data.
When considering the correlation between the IGAP gene-
based P-value and set size, we observe a statistically signiﬁ-
cant negative correlation (r = –0.083, P< 2.2 × 10−16) when
MAGMA-SUMMARY is used on summary data, indicating
that the higher the number of SNPs, the lower the set-based
P-value.
4 DISCUSSION
In this paper, we present a method for accounting for LD
in the calculation of a PRS. The resulting individual LD-
adjusted PRS can also be used for analyzing whether a set
of SNPs is associated with disease. This method combines
the advantages of PRS and spectral analysis of the genetic
data. The latter suggests a mathematically sound adjustment
for LD and includes a stabilization parameter (similar to ridge
regression) to cope with cases of extreme LD. It adjusts for
LD between SNPs and informs the analysis with previously
reported eﬀect sizes of a SNP's association with disease. In
the present study, we have chosen to do this adjustment using
the SNP-SNP correlation matrix; however, one could alterna-
tively use the SNP-SNP covariance matrix. For all examples
above, this gives very similar results. Partitioning the over-
all polygenic risk based on meaningful SNP sets, the method
allows both to test for signiﬁcance of association of these
sets (set-based analysis) and to provide individual set-speciﬁc
risk scores for subjects, which can further be used for risk
prediction of subphenotypes with respect to the SNP sets.
To assess the quality of the proposed approach, we compare
its use for set-based analysis with the widely used MAGMA
software. We show that POLARIS gives the correct Type I
error and its power lies between that of MAGMA applied to
the test dataset only and MAGMA applied to the combined
test and discovery datasets. In practice, researchers would use
all the available genotype data, and would use PRS-based
methods only if eﬀect sizes only are known for an additional
dataset.
POLARIS has four main advantages. (1) It produces a
risk score per person per set, unlike other set-based methods
which only provide a P-value for the strength of association
between the set and disease. This set risk score can be used
to stratify individuals for follow up studies (e.g., clinical tri-
als) and also prioritize genes for further functional studies
(e.g., animal models), supporting the development of preci-
sion medicines. (2) POLARIS can increase power by lever-
aging the discovery set to perform a self-contained test of
association in the test dataset. Another way to incorporate
the discovery set would be to use meta-analysis, however,
this detects an association in the combined set rather than the
test set only. This may be important when the test data dif-
fers in some way from the discovery data, for example diﬀer-
ent ethnicity, or diﬀerent phenotype. A good example might
be where the test sample uses diﬀerent diagnostic criteria to
measure the same phenotype (e.g., self-report questionnaire
for depression) and one wishes to validate these criteria by
showing that they show association to the same genes as those
implicated by the standard diagnosis. (3) POLARIS is not
inﬂated by set size. This is an issue previously reported in
summary statistic based approaches (Chatterjee et al., 2013;
Ruderfer, 2013) and is shown to be the case using MAGMA
on the IGAP summary statistic data. (4) The overall set asso-
ciation can easily be adjusted by population or any other
covariates.
For set-based analyses, in situations where only summary
statistics are available for part of the data, we suggest to use
the POLARIS method which unites advantages of the PRS
approach and the PCA-based set-based method, while taking
into account the LD structure for the genetic region of interest.
POLARIS can be used for any set of SNPs, for example,
the whole genome, genes, or pathways. Therefore, it has the
potential of data-driven discovery of pathways.
POLARIS can also be utilized in a number of cross-
disorder analyses to determine commonality between disor-
ders at a gene-based or pathway-based level. There are a num-
ber of common disorders for which the GWAS summary data
are publically available (e.g., Psychiatric Genomics Consor-
tium). The GWAS data for one disorder can be used to gener-
ate scores per person per gene in another disorder or subphe-
notype of interest, and thus test for overlap between disorders
at a gene-based level.
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The POLARIS method can be extended to add addi-
tional information into the score, such as rare variants from
exome sequencing studies. The POLARIS set-based method
is implemented into a freely accessible platform independent
software. Large sets have a high computational burden due to
the spectral decomposition of large correlation matrices; rec-
ommendations on maximum set size and the corresponding
required computational resource are included with the soft-
ware.
In this study, POLARIS was applied to test binary traits.
However, the POLARIS score can also be used as a variable
(along with other covariates) in regression models for quanti-
tative traits.
A limitation of the POLARIS implementation is that cur-
rently it is only available as a self-contained set-based method.
However, POLARIS can in principle be used as a competitive
set analysis, adjusting for the baseline level of association in
the data either by including a general PRS in the analysis or
comparing the set-based PRS to those generated from random
sets of genes (matched for number of genes/gene size/numbers
of SNPs) or random sets of SNPs (matched for LD, MAF, and
SNP density).
Another limitation of PRS-type approaches is the imper-
fect tagging of the underlying causal variants by SNPs and
imperfect eﬀect size estimates. The challenge of selecting the
true set of susceptibility SNPs for PRS modeling to capture
heritability has been pointed out (Chatterjee, Shi, & Garcia-
Closas, 2016). Our approach can use all SNPs in a set of inter-
est, even when in LD, and therefore any causal genotyped
SNPs will be included. If the causal SNPs are not present in
the sample, then the tagging SNPs only are used. The eﬀect
sizes of all SNPs in LD will be adjusted according to the LD
structure, not according to the causal/noncausal nature of the
SNP.
POLARIS is a valuable extension to standard PRS by
adjusting for LD between markers and removing the neces-
sity to LD prune data prior to analysis. POLARIS provides a
test of the set's association with disease while also producing
subject speciﬁc risk scores.
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